NCT02555124View on ClinicalTrials.gov

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-42847922 in Healthy Japanese Male Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 12, 2015

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions
Healthy
Interventions
DRUG

JNJ-42847922, 5 mg

Participants will receive single oral dose of 5 milligram (mg) of JNJ-42847922 on Day 1, fasted condition.

DRUG

JNJ-42847922, 20 mg

Participants will receive single oral dose of 20 mg of JNJ-42847922 on Day 1, fasted condition.

DRUG

JNJ-42847922, 40 mg

Participants will receive single oral dose of 40 mg of JNJ-42847922 on Day 1, fasted condition.

DRUG

Placebo

Participants will receive placebo on Day 1, fasted condition in Cohort A, Cohort B and Cohort C.

Trial Locations (1)

Unknown

Osaka

Sponsors
All Listed Sponsors
lead

Janssen Pharmaceutical K.K.

INDUSTRY